Complete Filing Data
IM Cannabis Corp. reported Cash And Cash Equivalents of $2.73 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean IM Cannabis Corp. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Sales And Marketing Expense | $5.4M | $7.1M | $10.8M | $11.5M | $6.7M | $3.8M |
| Profit Loss From Operating Activities | -$11.6M | -$10.2M | -$12.8M | -$30.8M | -$23.0M | -$8.2M |
| Profit Loss Before Tax | -$11.7M | -$12.8M | -$9.5M | -$26.1M | -$164.0K | -$28.5M |
| Profit Loss Attributable To Owners Of Parent | -$11.3M | -$10.6M | -$9.5M | -$188.9M | -$17.8M | -$28.7M |
| Profit Loss Attributable To Noncontrolling Interests | -$431.0K | -$1.2M | -$730.0K | -$2.4M | -$755.0K | -$36.0K |
| Profit Loss | -$11.8M | -$11.8M | -$10.2M | -$191.3M | -$18.5M | -$28.7M |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$2.5M | -$1.5M | -$663.0K | -$1.5M | $530.0K | -$124.0K |
| Other Comprehensive Income | -$2.4M | -$1.4M | -$625.0K | -$1.4M | $1.4M | $990.0K |
| Income Tax Expense Continuing Operations | $92.0K | -$1.0M | $771.0K | -$1.1M | $500.0K | $262.0K |
| Gross Profit | $9.7M | $8.5M | $9.8M | $9.2M | $6.3M | $10.5M |
| General And Administrative Expense | $9.5M | $8.0M | $11.0M | $21.5M | $17.2M | $11.5M |
| Cost Of Sales | $45.0M | $45.6M | $38.0M | $43.0M | $25.5M | $7.1M |
| Comprehensive Income Attributable To Owners Of Parent | -$13.8M | -$11.9M | -$10.6M | -$190.2M | -$16.4M | -$27.8M |
| Comprehensive Income Attributable To Noncontrolling Interests | -$346.0K | -$1.3M | -$205.0K | -$2.6M | -$752.0K | $64.0K |
| Comprehensive Income | -$14.2M | -$13.2M | -$10.9M | -$192.7M | -$17.1M | -$27.7M |
| Other Comprehensive Income Net Of Tax Gains Losses On Remeasurements Of Defined Benefit Plans | $48.0K | $67.0K | $38.0K | $59.0K | $21.0K | -$30.0K |
| Gross Profit Before Fair Value Adjustments | $9.7M | $8.5M | $10.8M | $11.3M | $8.6M | $8.8M |
| Restructuring Expenses | $0.00 | $0.00 | $617.0K | $4.4M | $0.00 | $0.00 |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax | $48.0K | $67.0K | $38.0K | $59.0K | $879.0K | $1.1M |
| Income Taxes Paid Classified As Operating Activities | $14.0K | $96.0K | $514.0K | $681.0K | $834.0K | $601.0K |
| Adjustments For Reconcile Profit Loss | $8.6M | $8.2M | $1.1M | $144.8M | -$4.2M | $22.8M |
| Other Comprehensive Income That Will Not Be Reclassified Net Of Tax Exchange Differences On Translation | -$894.0K | -$1.2M | $858.0K | $1.1M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $2.7M | $863.0K | $1.8M | $2.4M | $13.9M | $8.9M | $13.9M |
| Realized Fair Value Adjustment On Inventory Sold | $0.00 | $0.00 | -$984.0K | -$1.8M | -$8.6M | -$10.1M | |
| Right Of Use Asset Recognized With Corresponding Lease Liability | $254.0K | $40.0K | $309.0K | $613.0K | $1.7M | $107.0K | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $13.0K | $156.0K | $581.0K | $1.6M | $4.6M | $2.6M | |
| Gains Losses Recognised In Profit Or Loss Excluding Exchange Differences Fair Value Measurement Assets | $0.00 | $0.00 | -$984.0K | -$2.1M | -$2.3M | $1.7M | |
| Depreciation Rightofuse Assets | $318.0K | $351.0K | $594.0K | $1.9M | $1.6M | $209.0K | |
| Depreciation Property Plant And Equipment | $300.0K | $456.0K | $644.0K | $3.0M | $3.0M | $690.0K | |
| Cash Flows From Used In Operating Activities | $4.7M | -$1.1M | -$8.1M | -$12.6M | -$34.4M | -$7.9M | |
| Cash Flows From Used In Investing Activities | -$531.0K | -$470.0K | -$1.2M | -$1.5M | -$9.0M | -$4.1M | |
| Cash Flows From Used In Financing Activities | $1.1M | $3.8M | $9.4M | $4.8M | $48.7M | $6.7M | |
| Amortisation Intangible Assets Other Than Goodwill | $1.3M | $1.4M | $1.8M | $2.3M | $1.2M | $31.0K | |
| Adjustments For Increase Decrease In Trade Account Payable | $1.7M | $7.8M | -$6.1M | $11.3M | $5.6M | $2.1M | |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | $0.00 | -$96.0K | -$139.0K | -$63.0K | $28.0K | $59.0K | |
| Adjustments For Deferred Tax Expense | -$165.0K | -$150.0K | $394.0K | -$3.0M | $278.0K | -$66.0K | |
| Adjustments For Decrease Increase In Trade And Other Receivables | $4.1M | -$6.3M | $2.3M | $6.1M | -$6.6M | -$3.5M | |
| Property Plant And Equipment | $3.7M | $3.7M | $5.1M | $5.2M | $30.3M | ||
| Gains Losses On Fair Value Adjustment Biological Assets | $0.00 | $0.00 | $315.0K | -$6.3M | -$11.8M | ||
| Trade And Other Current Payables To Trade Suppliers | $12.1M | $11.2M | $9.2M | $15.3M | $14.0M | ||
| Rightofuse Assets | $401.0K | $451.0K | $1.3M | $1.9M | $18.2M | ||
| Retained Earnings | -$270.2M | -$258.9M | -$249.1M | -$239.6M | -$50.7M | ||
| Noncurrent Liabilities | $1.3M | $1.1M | $2.3M | $3.1M | $31.2M | ||
| Noncurrent Lease Liabilities | $54.0K | $171.0K | $815.0K | $1.1M | $17.8M | ||
| Noncurrent Assets | $9.0M | $15.8M | $24.5M | $28.0M | $206.2M | ||
| Liabilities | $35.4M | $36.0M | $35.1M | $36.9M | $82.4M | ||
| Intangible Assets Other Than Goodwill | $1.2M | $3.3M | $5.8M | $7.9M | $30.9M | ||
| Goodwill | $1.9M | $6.7M | $10.1M | $9.8M | $121.3M | ||
| Financial Assets At Fair Value Through Profit Or Loss | $1.8M | $1.6M | $2.3M | $2.4M | $2.4M | ||
| Equity Attributable To Owners Of Parent | -$3.7M | $5.2M | $14.5M | $22.7M | $201.2M | ||
| Equity And Liabilities | $31.7M | $39.2M | $48.8M | $60.7M | $287.4M | ||
| Deferred Tax Liabilities | $355.0K | $487.0K | $963.0K | $1.3M | $6.6M | ||
| Current Trade Receivables | $10.8M | $13.8M | $7.7M | $8.7M | $16.7M | ||
| Current Liabilities | $34.0M | $34.9M | $32.8M | $33.8M | $51.2M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Increase Decrease In Working Capital | -$7.8M | -$2.6M | -$1.5M | -$34.5M | $10.8M | $1.4M |
| Increase Decrease In Cash And Cash Equivalents | $1.9M | -$950.0K | -$636.0K | -$11.5M | $5.0M | -$5.0M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$3.5M | -$3.2M | -$796.0K | -$2.0M | -$329.0K | $213.0K |
| Proceeds From Issuing Shares | 5.1M | 944.0K | 1.7M | 3.8M | 28.1M | 0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted Earnings Loss Per Share | $-4.51 | $-4.45 | $-161.88 | $-6.70 | $-1.90 | |
| Basic Earnings Loss Per Share | $-4.51 | $-4.45 | $-157.83 | $-3.06 | $-1.90 | |
| Diluted Earnings Loss Per Share From Continuing Operations | $-2.67 | $-4.51 | $-4.45 | $-22.86 | $-3.62 | $-1.90 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Expense | $21.3M | $18.7M | $22.6M | $40.0M | $29.4M | $18.7M |
| Finance Income Cost | -$71.0K | -$2.6M | $3.3M | $4.7M | $22.9M | -$20.2M |
| Expense From Sharebased Payment Transactions With Employees | $14.0K | $369.0K | $225.0K | $2.6M | $5.4M | $3.4M |
| Finance Income | $3.4M | $2.2M | $7.0M | $6.7M | $23.5M | $277.0K |
| Finance Costs | $3.5M | $4.8M | $3.7M | $2.0M | $673.0K | $20.5M |
| Interest Paid Classified As Financing Activities | $41.0K | $52.0K | $63.0K | $1.4M | $1.3M | $68.0K |
| Increase Decrease Through Sharebased Payment Transactions | $14.0K | $369.0K | $225.0K | $3.8M | $7.5M | $3.4M |
| Adjustments For Sharebased Payments | $14.0K | $369.0K | $225.0K | $3.8M | $7.5M | $3.4M |
| Adjustments For Finance Income Cost | -$487.0K | -$1.9M | -$3.0M | -$6.5M | -$1.3M | -$72.0K |
| Interest Paid In Respect Of Loans | $2.5M | $2.1M | $1.7M | $902.0K | $261.0K | $0.00 |
| Adjustments For Decrease Increase In Inventories | $6.3M | $4.8M | $883.0K | -$19.7M | -$12.7M | |
| Shortterm Borrowings | $14.3M | $15.1M | $12.1M | $9.2M | $9.5M | |
| Reserve Of Sharebased Payments | $475.0K | $150.0K | $9.6M | $15.2M | $12.3M | |
| Reserve Of Exchange Differences On Translation | -$3.8M | -$1.3M | $95.0K | $1.3M | $2.6M | |
| Noncontrolling Interests | $115.0K | -$2.1M | -$769.0K | $1.1M | $3.7M | |
| Issued Capital | $270.5M | $265.0M | $253.9M | $245.8M | $237.7M | |
| Inventories | $4.3M | $3.2M | $10.0M | $16.6M | $29.4M |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.